How much funding has GondolaBio raised?

GondolaBio has raised $300.0M in total funding, most recently a Series A round.

Who are GondolaBio's investors?

GondolaBio's investors include Sanofi Ventures, Viking Global, Patient Square Capital, Sequoia Capital, Aisling Capital, Cormorant Asset Management.

When was GondolaBio founded?

GondolaBio was founded in 2024.

Where is GondolaBio headquartered?

GondolaBio is headquartered in Palo Alto, California, United States.

What industry is GondolaBio in?

GondolaBio operates in Biotech, Healthcare.

How many employees does GondolaBio have?

GondolaBio has 11-50 employees.

GondolaBio

Gondola Bio

Palo Alto, United States · Founded 2024 · $300.0M raised

Biotech

Healthcare

Headquarters: Palo Alto, California
Employees: 11–50
Founded: 2024
Business Model: B2B

Website: gondolabio.com
Total Funding: $300.0M
Last Round: $300.0M Series AAug 2024
Rounds: 1

About

GondolaBio is a clinical-stage biopharmaceutical company developing breakthrough therapeutics for patients living with genetic diseases. A sister company of BridgeBio Pharma, GondolaBio launched in 2024 with a decentralized approach to drug development. Its lead program PORT-77 is an oral small molecule ABCG2 inhibitor currently in Phase 2 development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).

Summary

GondolaBio is a Biotech company based in Palo Alto, United States, founded in 2024. It has raised $300.0M in total across 1 round, most recently a $300.0M Series A round in Aug 2024. Investors include Sanofi Ventures, Viking Global and Patient Square Capital.